Metacare Co (XKRX:118000) Research & Development: ₩0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XKRX:118000 Metacare Co Ltd XKRX:118000
42 GF Score
Price ₩1,328.00
GF Value ₩5,177.27
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Metacare Co Research & Development?

Metacare Co XKRX:118000 -2.99% 42 Research & Development is ₩0 Mil as of Jun. 2026. GuruFocus rates XKRX:118000 with a GF Score™ of 42/100 and a GF Value™ of ₩5,177.27 (Possible Value Trap). The stock has 9 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Metacare Co's Research & Development for the three months ended in Jun. 2026 was ₩0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 was ₩0 Mil.

Metacare Co  (XKRX:118000) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Metacare Co Research & Development Related Terms

Metacare Co Research & Development Historical Data

* Premium members only.

The historical data trend for Metacare Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metacare Co Research & Development Chart

Metacare Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1,181.96 0.00 0.00

Metacare Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XKRX:118000
42GF Score
Metacare Co Ltd XKRX:118000
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metacare Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₩0 Mil mean?
Metacare Co (XKRX:118000) has a Research & Development of ₩0 Mil as of Jun. 2026. Research and development expense is the total cost for research and development activities. View historical data on Metacare Co and its competitors.
Is Metacare Co's Research & Development too high?
Metacare Co's current Research & Development is ₩0 Mil. Overall, Metacare Co has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Metacare Co's Research & Development compare to LLY and JNJ?
Metacare Co's Research & Development of ₩0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Metacare Co and its competitors. Metacare Co's current Research & Development is ₩0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metacare Co stock overvalued right now?
Based on GuruFocus' analysis, Metacare Co (XKRX:118000) is currently considered Possible Value Trap. The stock's GF Value™ is ₩5,177.27, compared to a current price of ₩1,328.00 — trading 74.3% below its estimated fair value. The current Research & Development is ₩0 Mil. Metacare Co's overall GF Score™ is 42/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Metacare Co (XKRX:118000), the current Research & Development is ₩0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Metacare Co (XKRX:118000) Overvalued in 2026?

Based on GuruFocus' analysis, Metacare Co stock appears to be undervalued. The current stock price of ₩1,328.00 is trading 74.3% below its estimated GF Value™ of ₩5,177.27. GuruFocus considers Metacare Co to be Possible Value Trap.

Key valuation signals for XKRX:118000:

  • Research & Development: ₩0 Mil
  • GF Value™: ₩5,177.27 vs. price of ₩1,328.00 (74.3% below fair value)
  • GF Score™: 42/100 with 9 warning signs

No single metric tells the full story. See the XKRX:118000 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Metacare Co Business Description

Address 202, 156, Byeongjeomjungang-ro, Jinan-dong, Dream Buildiing, Gyeonggi-do, Hwaseong-si, KOR
Metacare Co Ltd formerly Smedi Co Ltd has established a hospital in Jeju and exports various types of medical equipments. The company also built its own hospital in China and India and plans to expand its business in Spain and Dubai. The Company and its subsidiaries are divided into pharmaceutical business, medical business, wireless device business, investment and others according to business characteristics by business sector.
42GF Score

Get the complete analysis for XKRX:118000

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₩1,328.00
Price
₩5,177.27
GF Value